Cullinan Oncology Llc Stock Probability of Future Stock Price Finishing Over 10.99
| CGEM Stock | USD 12.02 0.88 6.82% |
Cullinan |
Cullinan Oncology Target Price Odds to finish over 10.99
The tendency of Cullinan Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to stay above $ 10.99 in 90 days |
| 12.02 | 90 days | 10.99 | roughly 96.0 |
Based on a normal probability distribution, the odds of Cullinan Oncology to stay above $ 10.99 in 90 days from now is roughly 96.0 (This Cullinan Oncology LLC probability density function shows the probability of Cullinan Stock to fall within a particular range of prices over 90 days) . Probability of Cullinan Oncology LLC price to stay between $ 10.99 and its current price of $12.02 at the end of the 90-day period is about 6.35 .
Given the investment horizon of 90 days Cullinan Oncology has a beta of 0.48 suggesting as returns on the market go up, Cullinan Oncology average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Cullinan Oncology LLC will be expected to be much smaller as well. Additionally Cullinan Oncology LLC has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Cullinan Oncology Price Density |
| Price |
Predictive Modules for Cullinan Oncology
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cullinan Oncology LLC. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cullinan Oncology's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cullinan Oncology Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Cullinan Oncology is not an exception. The market had few large corrections towards the Cullinan Oncology's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Cullinan Oncology LLC, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Cullinan Oncology within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.42 | |
β | Beta against Dow Jones | 0.48 | |
σ | Overall volatility | 2.00 | |
Ir | Information ratio | -0.12 |
Cullinan Oncology Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Cullinan Oncology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Cullinan Oncology LLC can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Cullinan Oncology generated a negative expected return over the last 90 days | |
| Cullinan Oncology has high historical volatility and very poor performance | |
| Net Loss for the year was (153.16 M) with profit before overhead, payroll, taxes, and interest of 18.94 M. | |
| Cullinan Oncology LLC currently holds about 611 M in cash with (134.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cullinan Oncology has a poor financial position based on the latest SEC disclosures | |
| Over 96.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 8400 shares by Nadim Ahmed of Cullinan Oncology at 11.87 subject to Rule 16b-3 |
Cullinan Oncology Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Cullinan Stock often depends not only on the future outlook of the current and potential Cullinan Oncology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cullinan Oncology's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 41.5 M | |
| Cash And Short Term Investments | 467.1 M |
Cullinan Oncology Technical Analysis
Cullinan Oncology's future price can be derived by breaking down and analyzing its technical indicators over time. Cullinan Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Cullinan Oncology LLC. In general, you should focus on analyzing Cullinan Stock price patterns and their correlations with different microeconomic environments and drivers.
Cullinan Oncology Predictive Forecast Models
Cullinan Oncology's time-series forecasting models is one of many Cullinan Oncology's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Cullinan Oncology's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Cullinan Oncology LLC
Checking the ongoing alerts about Cullinan Oncology for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Cullinan Oncology LLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Cullinan Oncology generated a negative expected return over the last 90 days | |
| Cullinan Oncology has high historical volatility and very poor performance | |
| Net Loss for the year was (153.16 M) with profit before overhead, payroll, taxes, and interest of 18.94 M. | |
| Cullinan Oncology LLC currently holds about 611 M in cash with (134.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 13.4, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cullinan Oncology has a poor financial position based on the latest SEC disclosures | |
| Over 96.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 8400 shares by Nadim Ahmed of Cullinan Oncology at 11.87 subject to Rule 16b-3 |
Check out Cullinan Oncology Backtesting, Cullinan Oncology Valuation, Cullinan Oncology Correlation, Cullinan Oncology Hype Analysis, Cullinan Oncology Volatility, Cullinan Oncology History as well as Cullinan Oncology Performance. You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cullinan Oncology. If investors know Cullinan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cullinan Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.84) | Return On Assets (0.20) | Return On Equity (0.27) |
The market value of Cullinan Oncology LLC is measured differently than its book value, which is the value of Cullinan that is recorded on the company's balance sheet. Investors also form their own opinion of Cullinan Oncology's value that differs from its market value or its book value, called intrinsic value, which is Cullinan Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cullinan Oncology's market value can be influenced by many factors that don't directly affect Cullinan Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cullinan Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cullinan Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cullinan Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.